170 related articles for article (PubMed ID: 35640677)
1. Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.
Zhang Q; Wang HY; Nayak A; Nunez-Cruz S; Slupianek A; Liu X; Basappa J; Fan JS; Chekol S; Nejati R; Bogusz AM; Turner SD; Swaminathan K; Wasik MA
Am J Pathol; 2022 Aug; 192(8):1186-1198. PubMed ID: 35640677
[TBL] [Abstract][Full Text] [Related]
2. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
7. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
[TBL] [Abstract][Full Text] [Related]
8. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.
Zhu H; Vishwamitra D; Curry CV; Manshouri R; Diao L; Khan A; Amin HM
J Pathol; 2013 May; 230(1):82-94. PubMed ID: 23338972
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
12. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
13. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
15. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
16. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.
Shi B; Vishwamitra D; Granda JG; Whitton T; Shi P; Amin HM
Neoplasia; 2013 Jun; 15(6):669-83. PubMed ID: 23730215
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.
Zhang Q; Wang H; Kantekure K; Paterson JC; Liu X; Schaffer A; Paulos C; Milone MC; Odum N; Turner S; Marafioti T; Wasik MA
Blood; 2011 Sep; 118(11):3062-71. PubMed ID: 21765024
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
19. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Bischof D; Pulford K; Mason DY; Morris SW
Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
[TBL] [Abstract][Full Text] [Related]
20. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
Gu TL; Tothova Z; Scheijen B; Griffin JD; Gilliland DG; Sternberg DW
Blood; 2004 Jun; 103(12):4622-9. PubMed ID: 14962911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]